Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004937
Status:
COMPLETED
Last Update Posted:
2012-07-11
First Post:
2000-03-07
Brief Title:
Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Organization:
European Organisation for Research and Treatment of Cancer - EORTC
Study Overview
Official Title:
Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Patients With Glioblastoma Multiforme
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have recurrent glioblastoma multiforme
PURPOSE Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have recurrent glioblastoma multiforme
Detailed Description:
OBJECTIVES I Determine the efficacy acridine carboxzmide in terms of objective response rate and response duration in patients with glioblastoma multiforme II Determine the toxicities of this treatment regimen in this patient population
OUTLINE This is a multicenter study Patients receive acridine carboxamide IV continuously over days 1-5 Treatment repeats every 3 weeks for at least 2 courses and up to a maximum of 6 courses in the absence of disease progression or unacceptable toxicity Patients are followed every 6 weeks until disease progression
PROJECTED ACCRUAL A total of 14-25 patients will be accrued for this study
OUTLINE This is a multicenter study Patients receive acridine carboxamide IV continuously over days 1-5 Treatment repeats every 3 weeks for at least 2 courses and up to a maximum of 6 courses in the absence of disease progression or unacceptable toxicity Patients are followed every 6 weeks until disease progression
PROJECTED ACCRUAL A total of 14-25 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| XENOVA-XR500001498 | None | None | None |
| EORTC-16991G | None | None | None |